316 related articles for article (PubMed ID: 23452509)
1. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
Rao AD; Sugar EA; Chang DT; Goodman KA; Hacker-Prietz A; Rosati LM; Columbo L; O'Reilly E; Fisher GA; Zheng L; Pai JS; Griffith ME; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL; Koong A; Herman JM
Pract Radiat Oncol; 2016; 6(6):417-424. PubMed ID: 27552809
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
6. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
[TBL] [Abstract][Full Text] [Related]
7. Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):157-62. PubMed ID: 22543205
[TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
11. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
14. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
